GE Healthcare Technologies rises despite market downturn
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 12 2024
0mins
Source: Coinmarketcap
GE Healthcare Technologies Inc. saw a price increase of 5.03% as it crossed above its 5-day SMA, indicating a strong upward movement in its stock price. This rise occurred amid a broader market decline, with the Nasdaq-100 down 2.88% and the S&P 500 down 1.08%, suggesting a sector rotation where GE Healthcare is performing well despite overall market weakness. The company's resilience in this challenging environment may reflect investor confidence in its growth potential and operational stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 64.940
Low
80.00
Averages
92.25
High
105.00
Current: 64.940
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Western Digital Shares Drop 4.4% Amid Nasdaq 100 Performance
- Poor Stock Performance: Western Digital's shares are down 4.4% today, making it the worst performer in the Nasdaq 100, indicating market concerns about its short-term outlook, which could affect investor confidence.
- Strong Year-to-Date Gains: Despite today's decline, Western Digital has gained 272.1% year-to-date, reflecting a robust recovery over the past year that may attract long-term investors' interest.
- Market Dynamics: Alongside Western Digital, Qualcomm also saw a 4.4% drop, while GE HealthCare Technologies rose 3.2%, highlighting significant differences in market reactions to various tech companies, which could influence portfolio adjustment strategies.
- Investor Sentiment Fluctuations: The volatility in Western Digital's stock price may prompt investors to reassess the overall performance of tech stocks, especially in the current market environment, necessitating a cautious approach to short-term fluctuations in the tech sector.
See More
US Stocks Plunge Sharply, Tech Sector Hit Hard
- Market Sell-off: The S&P 500 fell 1.44%, the Dow Jones Industrial Average dipped 0.09%, and the Nasdaq 100 plummeted 3.29%, reflecting investor concerns over high valuations in tech stocks, leading to diminished market confidence.
- Asian Market Impact: Japan's Nikkei index dropped over 3%, while South Korea's Kospi index plummeted more than 10%, with foreign investors offloading over $2.5 billion in Kospi shares, indicating a global bearish sentiment towards tech stocks.
- Mixed Manufacturing Data: The US June manufacturing PMI unexpectedly rose to 55.7, surpassing expectations, indicating economic resilience; however, the Richmond Fed's manufacturing survey current conditions fell to 4, below the expected 8, suggesting uncertainty in economic recovery.
- Bond Market Reaction: Amid the stock sell-off, the 10-year T-note yield fell to 4.493%, while the 10-year breakeven inflation rate dropped to a 6-month low of 2.210%, reflecting increased demand for safe-haven assets.
See More
U.S. Stocks Plunge Sharply, Tech Sector Hit Hard
- Market Performance: The S&P 500 Index fell by 1.04%, reaching a 1.5-week low, while the Nasdaq 100 dropped by 2.67%, reflecting investor concerns over high valuations in tech stocks, which could impact future investment decisions.
- Asian Market Impact: Japan's Nikkei Index declined by over 3%, and South Korea's Kospi fell by more than 10%, with foreign investors offloading over $2.5 billion in Kospi shares, exacerbating negative sentiment and contributing to a global market downturn.
- Divergent Manufacturing Data: The U.S. June manufacturing PMI unexpectedly rose to 55.7, surpassing expectations, indicating economic resilience; however, the Richmond Fed manufacturing survey fell to 4, suggesting challenges in the economic recovery that may influence Fed policy.
- Bond Market Reaction: In response to the sharp equity selloff, the 10-year T-note yield dropped to 4.485%, indicating increased demand for safe-haven assets, although upcoming Treasury auctions may exert upward pressure on yields.
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Analysis of JAVA Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: JAVA's stock has a 52-week low of $63.67 and a high of $78.52, with the latest trade at $77.93, indicating that the stock is nearing its high point, reflecting market optimism about its future performance.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping to assess long-term trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding for ETFs allows for the identification of those experiencing significant inflows or outflows, enabling timely adjustments to investment strategies based on market dynamics.
See More
GE HealthCare Launches MIM Contour ProtégéAI+ 2.0 for Enhanced Radiation Therapy
- FDA Approval: GE HealthCare's MIM Contour ProtégéAI+ 2.0 has received 510(k) clearance from the FDA, marking a significant advancement in radiation oncology treatment planning, which is expected to greatly enhance clinical teams' efficiency and enable faster, personalized patient care.
- Technological Innovation: The new version introduces a Magnetic Resonance Brain model and an updated CT Male Pelvis model, expanding clinical capabilities across key anatomical regions, which is anticipated to improve the precision and efficiency of radiation therapy to meet increasingly complex patient needs.
- Process Automation: MIM Contour ProtégéAI+ 2.0 minimizes user interaction by enabling automatic contouring, significantly reducing manual effort and allowing clinical teams to focus more on developing personalized treatment plans, thereby enhancing the quality of patient care.
- Market Outlook: With the rising global cancer incidence, this innovative product from GE HealthCare not only addresses the market demand for efficient radiation therapy but also strengthens its competitive position in the medical technology sector through continuous technological iterations and updates.
See More
Western Digital Shares Drop 4.4% Amid Nasdaq 100 Performance
- Poor Stock Performance: Western Digital's shares are down 4.4% today, making it the worst performer in the Nasdaq 100, indicating market concerns about its short-term outlook, which could affect investor confidence.
- Strong Year-to-Date Gains: Despite today's decline, Western Digital has gained 272.1% year-to-date, reflecting a robust recovery over the past year that may attract long-term investors' interest.
- Market Dynamics: Alongside Western Digital, Qualcomm also saw a 4.4% drop, while GE HealthCare Technologies rose 3.2%, highlighting significant differences in market reactions to various tech companies, which could influence portfolio adjustment strategies.
- Investor Sentiment Fluctuations: The volatility in Western Digital's stock price may prompt investors to reassess the overall performance of tech stocks, especially in the current market environment, necessitating a cautious approach to short-term fluctuations in the tech sector.
See More
US Stocks Plunge Sharply, Tech Sector Hit Hard
- Market Sell-off: The S&P 500 fell 1.44%, the Dow Jones Industrial Average dipped 0.09%, and the Nasdaq 100 plummeted 3.29%, reflecting investor concerns over high valuations in tech stocks, leading to diminished market confidence.
- Asian Market Impact: Japan's Nikkei index dropped over 3%, while South Korea's Kospi index plummeted more than 10%, with foreign investors offloading over $2.5 billion in Kospi shares, indicating a global bearish sentiment towards tech stocks.
- Mixed Manufacturing Data: The US June manufacturing PMI unexpectedly rose to 55.7, surpassing expectations, indicating economic resilience; however, the Richmond Fed's manufacturing survey current conditions fell to 4, below the expected 8, suggesting uncertainty in economic recovery.
- Bond Market Reaction: Amid the stock sell-off, the 10-year T-note yield fell to 4.493%, while the 10-year breakeven inflation rate dropped to a 6-month low of 2.210%, reflecting increased demand for safe-haven assets.
See More
U.S. Stocks Plunge Sharply, Tech Sector Hit Hard
- Market Performance: The S&P 500 Index fell by 1.04%, reaching a 1.5-week low, while the Nasdaq 100 dropped by 2.67%, reflecting investor concerns over high valuations in tech stocks, which could impact future investment decisions.
- Asian Market Impact: Japan's Nikkei Index declined by over 3%, and South Korea's Kospi fell by more than 10%, with foreign investors offloading over $2.5 billion in Kospi shares, exacerbating negative sentiment and contributing to a global market downturn.
- Divergent Manufacturing Data: The U.S. June manufacturing PMI unexpectedly rose to 55.7, surpassing expectations, indicating economic resilience; however, the Richmond Fed manufacturing survey fell to 4, suggesting challenges in the economic recovery that may influence Fed policy.
- Bond Market Reaction: In response to the sharp equity selloff, the 10-year T-note yield dropped to 4.485%, indicating increased demand for safe-haven assets, although upcoming Treasury auctions may exert upward pressure on yields.
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Analysis of JAVA Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: JAVA's stock has a 52-week low of $63.67 and a high of $78.52, with the latest trade at $77.93, indicating that the stock is nearing its high point, reflecting market optimism about its future performance.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping to assess long-term trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding for ETFs allows for the identification of those experiencing significant inflows or outflows, enabling timely adjustments to investment strategies based on market dynamics.
See More
GE HealthCare Launches MIM Contour ProtégéAI+ 2.0 for Enhanced Radiation Therapy
- FDA Approval: GE HealthCare's MIM Contour ProtégéAI+ 2.0 has received 510(k) clearance from the FDA, marking a significant advancement in radiation oncology treatment planning, which is expected to greatly enhance clinical teams' efficiency and enable faster, personalized patient care.
- Technological Innovation: The new version introduces a Magnetic Resonance Brain model and an updated CT Male Pelvis model, expanding clinical capabilities across key anatomical regions, which is anticipated to improve the precision and efficiency of radiation therapy to meet increasingly complex patient needs.
- Process Automation: MIM Contour ProtégéAI+ 2.0 minimizes user interaction by enabling automatic contouring, significantly reducing manual effort and allowing clinical teams to focus more on developing personalized treatment plans, thereby enhancing the quality of patient care.
- Market Outlook: With the rising global cancer incidence, this innovative product from GE HealthCare not only addresses the market demand for efficient radiation therapy but also strengthens its competitive position in the medical technology sector through continuous technological iterations and updates.
See More
